Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 59,599	$ 69,593
Prepaid expenses and other current assets	618	914
Total current assets	60,217	70,507
Property and equipment, net	119	117
SAFE (see Note 1)	8,000
Right-of-use assets	184	228
Deposits and other assets	18	27
Total assets	68,538	70,879
Current liabilities:
Accounts payable	744	519
Accrued expenses	715	548
Accrued compensation expense	462	748
Accrued clinical trial expenses	219	462
Current operating lease liabilities	199	185
Total current liabilities	2,385	2,462
Long term operating lease liabilities		52
Total liabilities	2,385	2,514
Stockholders’ equity:
Preferred stock, no par value, 10,000 shares authorized; none outstanding
Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 39,409 as of March 31, 2022 and December 31, 2021	347,940	347,940
Additional paid-in capital	49,402	49,389
Accumulated other comprehensive loss	(392)	(379)
Accumulated deficit	(330,797)	(328,585)
Total stockholders’ equity	66,153	68,365
Total liabilities and stockholders’ equity	$ 68,538	$ 70,879